Cited by 177Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Lewy Body Pathology in Alzheimer's Disease

Kotzbauer, Paul T., Tojanowski, John Q., Lee, Virginia M. V.·2001·Journal of Molecular Neuroscience

Abstract

Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer's disease (AD). However the typical anatomic distribution of Lewy bodies in AD is distinct from PD. The most common site of occurrence is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Other common sites of occurrence include the periamygdaloid and entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of Lewy bodies in familial AD cases suggests that like neurofibrillary tangles, the formation of Lewy bodies can be induced by the pathological state caused by Abeta-amyloid overproduction. The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.

Integrity signals

Registry

Crossref · 10.1385/jmn:17:2:225

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • α-Synuclein is a protein that can accumulate in the neurons of patients with Parkinson disease.

    “Other targets in neurology where a PROTAC modality may offer clear advantages over current therapeutic agents include α-synuclein, a protein that can accumulate in the neurons of patients with Parkinson disease192.”

    From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [192]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V.
Affiliations
University of Pennsylvania (US)
Corresponding author
Lee, Virginia M. V.
Venue
Journal of Molecular Neuroscience
Published
2001
Volume
17
Issue
2
Pages
225-232
ISSN
0895-8696 (ISSN-L)
OpenAlex
W2081331575
Cited by
177
References
82
Citations by year
2026: 5 · 2025: 20 · 2024: 9 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 9 · 2012: 9
FWCI
4.59
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Molecular Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Lewy bodies, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, alpha-synuclein, amygdala, amyloid plaques, neurofibrillary tangles, familial Alzheimer's disease, substantia nigra, entorhinal cortex, brainstem, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Nerve Tissue Proteins, Neurons, Amyloid beta-Peptides, Lewy Bodies, tau Proteins, Point Mutation, Oxidative Stress, Synucleins, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review